Previous Close | 26.05 |
Open | 25.76 |
Bid | 25.52 x 800 |
Ask | 25.55 x 800 |
Day's Range | 25.30 - 26.20 |
52 Week Range | 3.96 - 36.64 |
Volume | |
Avg. Volume | 814,770 |
Market Cap | 1.494B |
Beta (5Y Monthly) | 1.42 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.57 |
Earnings Date | May 08, 2023 - May 12, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 46.64 |
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue without modification and proceed to evaluate 320 mg doseSOUTH SAN FRANCISCO, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced that, following a positive independent Data Safety Monitoring Board (DSMB) safe
Pliant Therapeutics ( NASDAQ:PLRX ) Full Year 2022 Results Key Financial Results Net loss: US$123.3m (loss widened by...
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -2.86% and 27.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?